Hey LARVOL fam! Today, we've managed to grab some precious moments with our very own VP Oncology, Dr. Mark Gramling. We've got science, guitars, and comedy skits on the docket, so let's dive right in!
Dr. Mark Gramling: I’ve been with LARVOL in two separate tentures. For my first, I focused on developing services supporting healthcare and clinical trials. In my second tenure, I’ve focused on building and developing existing and new products in oncology.
Dr. Mark Gramling: I like to describe myself as a “recovering scientist”. For my undergrad, I studied biochemistry and microbiology and figured if I did that I would pursue a PhD in pathology examining disease mechanisms. I found the preclinical models of oncology the most intriguing and chose to continue pursuing that in my postdoctoral studies. After my post-doctoral studies, I saw a job posting for supporting market intelligence reports that was originally part-time for LARVOL - and I guess I’ve never turned back.
Dr. Mark Gramling: There is obviously the remote element - of which LARVOL has been innovative for many years. I love being able to connect to a global team and being part of a company with a team that is always exploring, experimenting, and growing to try new things to support our customers is particularly fulfilling.
Dr. Mark Gramling: Whether a strength or a weakness, I always think about people and my teams first. When you know we’re all dependent upon each other across 10 different time zones to achieve a collective goal, it’s hard not to be motivated by that.
Dr. Mark Gramling: We obviously use both virtual reality but also video conferences, so it wouldn’t surprise my colleagues that I have guitars hanging up all over my house. As much as I try to tell a joke or two in meetings, they might also be surprised how much time I spend delving into the history and the latest in stand up and sketch comedy.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm